GLP1R and type 2 diabetes mellitus: In the last years, glucagon-like peptide 1 receptor agonists (GLP1-RA) including liraglutide, semaglutide, albiglutide, dulaglutide, and efpeglenatide have been shown to decrease the risk of cardiovascular (CV) events in patients with type 2 diabetes and atherosclerotic CV disease or at high CV risk (Gerstein et al., 2021; Tuttle et al., 2021).